New Brunswick Scientific Reports Second Quarter and First Half 2007 Financial Results

EDISON, N.J., Aug. 13  /PRNewswire-FirstCall/ -- New Brunswick Scientific Co., Inc. (the "Company" or "NBS") (NASDAQ:NBSC), today announced financial results for the 2007 second quarter and first six months ended June 30, 2007.

Second quarter and first half 2007 net sales of $21.0 million and $36.0 million, respectively, exceeded last year's $18.6 million and $35.6 million for the comparable periods. The increase in second quarter revenues reflects higher demand for the Company's products and the resumption of routine shipments in the second quarter of the Company's U.S. manufactured products after the first quarter curtailment due to the implementation of its Oracle Enterprise Resource Planning (ERP) system. 2007 domestic sales rose 1.9% during the quarter ended June 30, 2007 and declined 9.6% for the six months ended June 30, 2007, while international sales posted respective increases of 21.3% and 8.4% from the comparable prior year periods.  The favorable effects of foreign currency translation on net sales for the three and six months ended June 30, 2007 were $545,000 and $1,286,000, respectively.

NBS President and Chief Executive Officer James Orcutt stated: "Higher shipments of our U.S. manufactured products during the year's second quarter, along with the favorable effects of foreign currency translation, contributed to the increase in revenues for the three and six month periods.  We are encouraged by the increase in new orders of 31.9% and 31.3%, respectively, for the second quarter and first half of 2007 versus the 2006 comparable periods and an $18 million backlog with which we enter the third quarter of 2007."

Net income for the quarter ended June 30, 2007 was $966,000, or $0.10 per diluted share, compared with net income for the quarter ended July 1, 2006, of $1,017,000, or $0.11 per diluted share. Net income for the six months ended June 30, 2007 was $1.1 million, or $0.11 per diluted share, versus $1.6 million, or $0.17 per diluted share, for the first half of 2006.

Gross margin for the three months ended June 30, 2007 decreased 4.4% to 36.8% from 41.2% from the 2006 comparable quarter.  This decrease in gross margin is primarily attributable to the unfavorable effects that the lower absorption of labor and overhead had on our gross margins for inventory which was manufactured in the first quarter of 2007 and sold during the second quarter of 2007.  For the six months ended June 30, 2007 gross margin decreased 2.7% to 38.3% from 41.0% from the 2006 comparable six month period. This decrease in gross margin was primarily due to lower absorption of labor and overhead due to the effect the ERP system's implementation had on the manufacturing process at the Company's largest facility, which temporarily slowed down manufacturing activities.

Selling, general and administrative expenses as a percentage of net sales amounted to 24.6% and 28.0%, respectively, for the quarter ended June 30, 2007 and six month period ended June 30, 2007. This compares with 26.5% and 26.8% for the comparable prior year periods. For the three and six months ended June 30, 2007, selling, general and administrative expenses included merger related costs of $143,000 and $162,000, respectively.  The effects of foreign currency translation for the second quarter and first half had an unfavorable effect on selling, general and administrative expenses of $128,000 and $307,000, respectively.  Research, development and engineering expenses decreased 6.8% for the quarter and 12.2% for the half versus last year's respective periods. R&D expenses for 2007 reflect reduced costs associated with prototypes, tooling and certifications versus the 2006 periods.

Income from operations for the quarter ended June 30, 2007 and six months ended June 30, 2007 was $1.5 million and $1.6 million, respectively, compared with $1.6 million and $2.6 million for the respective year ago periods.

Orcutt continued: "As previously announced, New Brunswick Scientific has entered into a merger agreement with Eppendorf Incorporated subject to customary closing conditions and shareholder approval. The merger is proceeding on plan and we have filed our preliminary proxy with the Securities and Exchange Commission."

To be added to New Brunswick Scientific's e-mail distribution list, please click on the link below: http://www.clearperspectivegroup.com/clearsite/nbsc/emailoptin.html

About New Brunswick Scientific

New Brunswick Scientific Co., Inc., is a leading global innovator providing a comprehensive line of equipment and instrumentation for the life science industry. The Company's products are used in the creation, maintenance and control of physical and biochemical environments required for the growth, detection and storage of microorganisms for medical, biological and chemical applications, environmental research and commercial products. Established in 1946, the Company is headquartered in Edison, New Jersey, with sales and distribution facilities located in the United States, Europe and Asia. News releases and other information on the Company are available on the Internet at: http://www.nbsc.com/

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will" or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the Company. The forward-looking statements include a number of risks and uncertainties, which are detailed in Part I, Item 1A, "Risk Factors" of the Company's Annual Reports on Form 10-K, and other risk factors identified herein or from time to time in its periodic filings with the Securities and Exchange Commission. Forward-looking statements are based on management's current expectations and assumptions, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from these expectations and assumptions due to changes in our ability to consummate the merger with Eppendorf Incorporated, global political, economic, business, competitive, market, regulatory and other factors. The Company undertakes no obligation to publicly update or review any forward-looking information, whether as a result of new information, future developments or otherwise.

                        -Financial Tables Follow-

           NEW BRUNSWICK SCIENTIFIC CO., INC., AND SUBSIDIARIES
                  CONSOLIDATED STATEMENTS OF OPERATIONS
                 (In thousands, except per-share amounts)
                               (Unaudited)


                                   Three Months Ended     Six Months Ended
                                   June 30,    July 1,   June 30,    July 1,
                                     2007       2006       2007       2006

  Net sales                       $ 21,027   $ 18,586   $ 36,019   $ 35,553
  Operating costs and expenses:
    Cost of sales                   13,296     10,922     22,239     20,982
    Selling, general and
     administrative expenses         5,172      4,918     10,069      9,544
    Research, development and
     engineering expenses            1,069      1,147      2,135      2,433

      Total operating costs
       and expenses                 19,537     16,987     34,443     32,959

  Income from operations             1,490      1,599      1,576      2,594
  Other income (expense):
    Interest income                     66         86        151        174
    Interest expense                   (18)       (77)       (36)      (167)
    Other, net                         (35)       (35)       (42)       (65)
                                        13        (26)        73        (58)
  Income before income tax expense   1,503      1,573      1,649      2,536
  Income tax expense                   537        556        591        936
  Net income                         $ 966    $ 1,017    $ 1,058    $ 1,600
  Basic income per share            $ 0.10     $ 0.11     $ 0.11     $ 0.18
  Diluted income per share          $ 0.10     $ 0.11     $ 0.11     $ 0.17

  Basic weighted average number of
   shares outstanding                9,225      9,175      9,222      9,111
  Diluted weighted average number of
   shares outstanding                9,249      9,232      9,268      9,172



                SELECTED CONSOLIDATED BALANCE SHEET ITEMS
                          (Dollars in thousands)
                               (Unaudited)

                                           June 30, 2007   December 31, 2006

  Cash and cash equivalents                    $ 6,796           $8,082
  Accounts receivable, net                      14,169           15,520
  Inventories                                   15,774           13,483
  Property, plant and equipment, net             8,844            8,921
  Total assets                                  60,438           59,117
  Accounts payable and accrued expenses         11,220           11,366
  Long-term debt, net of current installments       65              874
  Shareholders' equity                          46,966           45,146
  Working capital                               28,071           27,333
  Current ratio                               3.3 to 1         3.3 to 1


DATASOURCE: New Brunswick Scientific Co., Inc.



CONTACT:  Thomas Bocchino, Vice President, Finance and Treasurer of New

Brunswick Scientific Co., Inc., [phone], ; or

Matthew J. Dennis, CFA, for NBS Investor Relations, of Clear Perspective

Group, LLC, [phone], 



Web site:  http://www.nbsc.com/ 

Copyright